+

WO1994013252A1 - Procede permettant de stimuler la production de la heme oxygenase au moyen de la vitamine b12 - Google Patents

Procede permettant de stimuler la production de la heme oxygenase au moyen de la vitamine b12 Download PDF

Info

Publication number
WO1994013252A1
WO1994013252A1 PCT/US1993/012024 US9312024W WO9413252A1 WO 1994013252 A1 WO1994013252 A1 WO 1994013252A1 US 9312024 W US9312024 W US 9312024W WO 9413252 A1 WO9413252 A1 WO 9413252A1
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
heme oxygenase
composition
skin
formulations
Prior art date
Application number
PCT/US1993/012024
Other languages
English (en)
Inventor
Richard D. Levere
Nadar G. Abraham
Michal L. Schwartzman
Michael W. Dunn
Original Assignee
Hemogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hemogen, Inc. filed Critical Hemogen, Inc.
Priority to AU57472/94A priority Critical patent/AU680222B2/en
Priority to EP94903578A priority patent/EP0673236A4/fr
Publication of WO1994013252A1 publication Critical patent/WO1994013252A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20—Halogens; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/001—Preparations for care of the lips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations

Definitions

  • This invention relates to a method for treating various disorders characterized by either or both of (i) an insufficient amount of heme oxygenase, and (ii) an excess of 12(R)-hydroxyeicosatetraenoic acid. It has been found that one may regulate the amounts of these materials via administration of vitamin B12.
  • the patent describes how, in the eye, induction of heme oxygenase levels effectively decreased 12(R)-HETE and 12(R)- DIHETE levels.
  • U.S. patent application 07/990,793, cited supra. discusses the use of vitamin B12 as an effective agent for treating conditions characterized by excessive cellular exfoliation and/or hyperkeratinization. These conditions which affect the skin and/or scalp, include dandruff (Seborrhea sicca) , seborrheic dermatitis, acne vulgaris, rosacea, Herpes zoster, psoriasis and eczema, among others.
  • dandruff Seborrhea sicca
  • seborrheic dermatitis acne vulgaris
  • rosacea Herpes zoster
  • psoriasis and eczema among others.
  • Additional conditions which exhibit excessive exfoliation include various rashes and allergies, including responses to poison oak, ivy and sumac, allergies, chicken pox, insect bites, athlete's foot, actinic keratitis, contact dermatitis, diaper rash, and all forms of pruritus.
  • Various topical formulations for alleviating these conditions are described.
  • the shampoos contain a primary detergent, such as a fatty alcohol sulfate, an ether sulfate, a sarconisate or some other anionic material, as well as vitamin B12.
  • Additional materials may include aqueous solutions of a soft soap, preservatives, sequestrants, colors, and perfumes.
  • compositions and/or shampoos which contain, as their effective ingredient, vitamin B12.
  • Formulations which contain the vitamin in amounts ranging from 0.1 to about 10.0% by weight are described as being preferred, with those containing from about 0.1 weight percent to about 1.0 weight percent vitamin B12 being especially preferred.
  • compositions containing vitamin B12 may be used as topical formulations for increasing heme oxygenase levels in the skin and other forms of non-ocular epidermis.
  • Such formulations include not only the standard topicals and shampoos, but also formulations such as mouthwashes, gavages, etc., which can be used in formulations for treating oral epidermic cells, aerosols for treating nasal tissue, suppositories, and so forth. The invention is described in greater detail in the disclosure which follows.
  • the invention relates to methods for increasing heme oxygenase levels in non-ocular epidermal tissue via administration of a heme oxygenase increasing effective amount of vitamin B12 to a subject in need thereof.
  • the method involves treating skin in the manner indicated, including oral and nasal mucosa.
  • the invention also involves compositions useful in the treatment of such conditions, where the compositions include sufficient vitamin B12 to stimulate increased production of heme oxygenase levels, where the compositions do not include any other vitamins or vitamin derivatives.
  • the conditions which can be so treated include those where non necrotizing thermal injury has occurred.
  • Such conditions include sunburn and other conditions caused by excessive exposure to ultraviolet irradiation, actinic keratitis, burns caused by, e.g., exposure to hot or boiling water or hot metal surfaces, and so forth. Additionally, conditions characterized by skin eruptions and/or inflammation, including herpes simplex and herpes zoster, psoriasis, acne, and so forth, may also be treated in the thus described manner.
  • the invention embraces formulation useful in the treatment of conditions where increasing the level of heme oxygenase and/or decreasing the level of 12R(HETE) is desirable.
  • the formulations are characterized by an amount of vitamin B12 sufficient to stimulate increased production of the enzymes, and do not contain any other vitamins or vitamin derivatives.
  • the compositions may include other materials, as described infra, including a pharmacologically acceptable carrier.
  • compositions of the invention may include merely an amount of vitamin B12 sufficient to stimulate heme oxygenase and a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier e.g., water, alcohol, and water.
  • shampoos including liquids, lotions, gels, emulsions, powders, creme rinses, and other standard formulations of shampoos.
  • a standard shampoo in accordance with the invention may include, e.g. , the following formulation: Ingredient sodium lauryl sulfate(30%) lauramide DEA disodium EDTA
  • This formulation is a pearlescent or opaque liquid.
  • any of the standard shampoos available over the counter, as well as those available only by prescription may be used as carriers for the active ingredient, i.e., vitamin B12.
  • any of the standard skin cremes, lotions, gels, liquids, sprays, etc. may be modified to incorporate vitamin B12 therein.
  • standard mouthwash formulations may be adapted for the invention by incorporating vitamin B12 therein.
  • Vitamin B12 refers to all forms of the molecule, as well as to its salts.
  • the fundamental portion of the molecule for purposes of the invention is the coordination compound formed by cobalt and its porphyrin ring. It is to be understood that the vitamin may be treated to render it more soluble in the particular carrier of choice, via, e.g., reacting it to form an acid addition salt, or in any other way which does not impact the fundamental portion of the molecule described supra.
  • the invention also encompasses therapeutic methods for treating the conditions discussed herein by administering an amount of vitamin B12 sufficient to stimulate heme oxygenase production to the site of the condition.
  • the dose will vary, depending upon the condition, the patent and the severity of the condition, but a general range may be to use a composition containing anywhere from 0.1 to 10.0% by weight of vitamin B12. A particular preferred range runs from about 0.1 weight percent to about 2.0% weight percent, relative to the composition.
  • Example 1 The efficacy of the compositions in accordance with this invention is shown in the following examples.
  • Example 1 The efficacy of the compositions in accordance with this invention is shown in the following examples.
  • a standard shampoo (“IVORY”) , contains water, ammonium laureth sulfate, ammonium lauryl sulfate, glycol distearate, cocoamide dea, dimethicone, citric acid, sodium hydroxide, fragrance, EDTA, xylene sulfonate, ammonium chloride, methyl chloroisothiazolinone, and methyl isothiazolinone.
  • This "over the counter" composition was modified by including vitamin B12 (1 mg per 100 ml of shampoo, i.e., 1% by weight).
  • the shampoos were provided to subjects having severe dandruff problems. Subjects were shampooed once per day with the formulations, and after 2-4 days, scurf was absent. The shampoos was applied for a period of 10 days, during which time no dandruff was evident.
  • Cell line CCD-860SK is a human skin fibroblast cell line which is publicly available from the American Type Culture Collection. Cell cultures of this line were propagated in Iscove's modified Dulbecco's medium supplemented with 10% fetal bovine system. Following propagation, they were grown in 175 cm 2 Falcon tissue culture flasks, using Iscove's modified Dulbecco's medium, supplemented with 10% (v/v) heat inactivated fetal bovine serum, 50 U penicillin/ml, 50 ug streptomycin/ml, and 2 mM glutamine.
  • the cells were then seeded into culture flasks at a concentration of lxlO 5 cells/ml, and incubated at 37°C in a humidified 5% C0 2 /95% air chamber. After three days, old media were removed, and replaced with fresh media.
  • icrosomes were prepared as described by Tenhunen et al., J. Biol. Chem. 244: 6388-6394 (1969) , incorporated by reference herein.
  • the activity of microsomal heme oxygenase was then determined, using 0.5-1 mg protein in an incubation medium as described by Tenhunen et al., supra.
  • Total protein was then determined using the classic method of Lowry et al., J. Biol. Chem. 193: 265-175 (1951) , using bovine serum albumin as standard.
  • Vitamin B 12 (10 ⁇ M) 297 ⁇ 12
  • Results are expressed as the mean ⁇ SD. *p ⁇ .001 vs. control.
  • RNA message for heme oxygenase The second half of the experiment discussed in example 3 involved the determination of RNA message for heme oxygenase.
  • a probe was prepared.
  • the probe was the 833 base pair ECORI/Hindlll fragment prepared from vector pRHOI.
  • This vector is a plasmid which contains full length cDNA for heme oxygenase, as described by Shibahara et al., J. Biol. Chem. 262: 12889-12892 (1987), which is incorporated by reference in its entirety.
  • the probes was obtained following restriction endonuclease treatment, via electrophoresis in low temperature gelling agarose, followed by excision of the band described by Abraham et al., Int. J. Cell Cloning 9: 185-210 (1991).
  • the DNA was labelled with [ ⁇ - 32 P]dCTP using a standard multiprime labelling kit, achieving specific activity of 1-2 cpm/ug. In the experiments which follow, it was used at a concentration of 10 6 cpm/ml relative to the hybridization mixture.
  • the thus prepared probe was used in Northern Blot analysis of total cellular RNA.
  • a minimum of 5xl0 7 cells per sample were pelleted, using the classic method of Chirgwin et al., Biochem. 18: 5294-5299 (1977).
  • Ten microgram quantities of the fibroblast total RNA were denatured and size separated via electrophoresis at 100 v for 2.5 hours in 1.5% (w/v) agarose formaldehyde, followed by blotting to nitrocellulose membranes.
  • the blotted RNA was hybridized with the labelled probes discussed supra. following Shibahara et al, supra. Post hybridization washes were carried out at 45°C in lxSSC (150 mM NaCl/15 mM Na citrate), and 0.1% SDS. Binding was determined using standard autoradiography.
  • Lane 1 is a control. Lane 2 used vitamin B12 at 10 ⁇ M. The third lane shows results from vitamin B12 at 100 ⁇ M, whereas lane 4 shows the results where SnCl 2 was used at 100 uM. Finally, lane 5 shows the results using 10 uM of heme. It will be seen that vitamin B12 clearly increased the amount of message. This correlates to the results supra. showing that enzyme activity increased, thus indicating increased levels of heme oxygenase in the target.
  • compositions which are compositions containing sufficient vitamin B12 to stimulate production of heme oxygenase when applied to the intended site. These compositions are designed for topical use, such as the skin cremes, lotions, shampoos, mouthwashes, nasal aerosols, suppositories and so forth described supra. As indicated, the compositions preferably contain anywhere from about 0.1% to about 10.0% by weight of vitamin B12, in combination with other ingredients. Such formulations should not contain any other vitamins or vitamin derivatives.
  • the invention involves methods for treating disorders of the epidermis where increased levels of heme oxygenase are desirable. These methods involve applying to the site of the condition an amount of vitamin B12 sufficient to provoke and or to stimulate increased levels of heme oxygenase in the epidermis. Specifically excluded from treatment in this invention is treatment of the eye. Disorders contemplated for treatment include those described in the Summary of the Invention, supra, and for that reason are not reiterated here.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)

Abstract

Selon l'invention, la vitamine B12 est utilisée pour stimuler la production de la hème oxygénase. En conséquence, la teneur en molécules 12(R)-HETE et 12(R)-DIHETE est réduite. Différentes compositions topiques contenant de la vitamine B12, mais aucune autre vitamine, sont également décrites.
PCT/US1993/012024 1992-12-10 1993-12-09 Procede permettant de stimuler la production de la heme oxygenase au moyen de la vitamine b12 WO1994013252A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU57472/94A AU680222B2 (en) 1992-12-10 1993-12-09 Method for stimulating production of heme oxygenase using vitamin B12
EP94903578A EP0673236A4 (fr) 1992-12-10 1993-12-09 Procede permettant de stimuler la production de la heme oxygenase au moyen de la vitamine b12.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99079392A 1992-12-10 1992-12-10
US07/990,793 1992-12-10
US7783493A 1993-06-15 1993-06-15
US08/077,834 1993-06-15

Publications (1)

Publication Number Publication Date
WO1994013252A1 true WO1994013252A1 (fr) 1994-06-23

Family

ID=26759730

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/012024 WO1994013252A1 (fr) 1992-12-10 1993-12-09 Procede permettant de stimuler la production de la heme oxygenase au moyen de la vitamine b12

Country Status (4)

Country Link
EP (1) EP0673236A4 (fr)
AU (1) AU680222B2 (fr)
CA (1) CA2151148A1 (fr)
WO (1) WO1994013252A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028907A3 (fr) * 1993-06-15 1995-02-02 Karsten Klingelhoeller Utilisation des corrinoides en application locale pour les affections cutanees
WO1996009038A3 (fr) * 1994-09-22 1996-06-13 William Harvey Research Limite Modification de l'activite et/ou des niveaux de l'heme-oxygenase pour la regulation pharmaceutique de l'inflammation
US6066333A (en) * 1994-09-22 2000-05-23 William Harvey Research Limited Pharmaceutical control of inflammation
AU723677B2 (en) * 1994-09-22 2000-08-31 William Harvey Research Limited Pharmaceutical control of inflammation
EP1128835A4 (fr) * 1998-12-28 2002-05-02 Allergy Ltd Llc Utilisation de la cyanocobalamine (vitamine b 12?) pour le traitement des allergies
WO2002003942A3 (fr) * 2000-07-06 2002-05-02 Planet Biotech Inc Compositions a complexe de la vitamine b utilisee pour la protection contre les lesions cellulaires provoquees par le rayonnement ultraviolet
DE10053155A1 (de) * 2000-10-26 2002-05-08 Erika Jungkeit Verwendung eines Multivitaminpräparats zur Behandlung der Schuppenflechte
DE10130846A1 (de) * 2001-06-28 2003-01-16 Regeneratio Pharma Ag Verwendung von Corrinoiden zur Anwendung bei Hauterkrankungen

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503037A (en) * 1981-03-17 1985-03-05 Human Oltoanyagtermel/o/ es Kutato Intezet Composition for the treatment of epithelial injuries and process for the preparation thereof
US5053222A (en) * 1989-06-07 1991-10-01 Shiseido Company Ltd. Hair cosmetic composition
US5080908A (en) * 1989-08-31 1992-01-14 Takeda Chemical Industries, Ltd. Vitamin b12 composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4007266A (en) * 1968-05-03 1977-02-08 Choay S.A. Pharmaceutical composition containing vitamin B12, process of making the same and method of treatment
US3577537A (en) * 1970-03-09 1971-05-04 Merck & Co Inc Topical administration of vitamin b-12
DE2619100A1 (de) * 1976-05-03 1977-11-10 Koehler Valentin Verwendung von glucuronsaeure oder glucuronsaeure-gamma-lacton als hemmstoff fuer beta-glucuronidase
US4724231A (en) * 1985-04-16 1988-02-09 Nastech Pharmaceutical, Inc. Nasel compositions containing vitamin B12
DE3682862D1 (de) * 1985-04-16 1992-01-23 Nastech Pharm Co Aerosolmittel zur nasenverstaeubung von vitamin b 12.
US5102670A (en) * 1990-09-14 1992-04-07 Abraham Nader G Method for treating eye disorders by reducing 12(r)-hydroxyeicosatetraenoic acid and 12(r)-dihydroxyeicosatrienoic acid levels

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503037A (en) * 1981-03-17 1985-03-05 Human Oltoanyagtermel/o/ es Kutato Intezet Composition for the treatment of epithelial injuries and process for the preparation thereof
US5053222A (en) * 1989-06-07 1991-10-01 Shiseido Company Ltd. Hair cosmetic composition
US5080908A (en) * 1989-08-31 1992-01-14 Takeda Chemical Industries, Ltd. Vitamin b12 composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0673236A4 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028907A3 (fr) * 1993-06-15 1995-02-02 Karsten Klingelhoeller Utilisation des corrinoides en application locale pour les affections cutanees
US5798341A (en) * 1993-06-15 1998-08-25 Klingelhoeller; Karsten Use of cobalamins for topical treatment of skin disorders
WO1996009038A3 (fr) * 1994-09-22 1996-06-13 William Harvey Research Limite Modification de l'activite et/ou des niveaux de l'heme-oxygenase pour la regulation pharmaceutique de l'inflammation
US6066333A (en) * 1994-09-22 2000-05-23 William Harvey Research Limited Pharmaceutical control of inflammation
AU723677B2 (en) * 1994-09-22 2000-08-31 William Harvey Research Limited Pharmaceutical control of inflammation
EP1128835A4 (fr) * 1998-12-28 2002-05-02 Allergy Ltd Llc Utilisation de la cyanocobalamine (vitamine b 12?) pour le traitement des allergies
WO2002003942A3 (fr) * 2000-07-06 2002-05-02 Planet Biotech Inc Compositions a complexe de la vitamine b utilisee pour la protection contre les lesions cellulaires provoquees par le rayonnement ultraviolet
AU2001272274B2 (en) * 2000-07-06 2007-01-18 Planet Biotech Inc. B complex vitamin compositions that protect against cellular damage caused by ultraviolet light
DE10053155A1 (de) * 2000-10-26 2002-05-08 Erika Jungkeit Verwendung eines Multivitaminpräparats zur Behandlung der Schuppenflechte
DE10130846A1 (de) * 2001-06-28 2003-01-16 Regeneratio Pharma Ag Verwendung von Corrinoiden zur Anwendung bei Hauterkrankungen

Also Published As

Publication number Publication date
AU5747294A (en) 1994-07-04
AU680222B2 (en) 1997-07-24
EP0673236A4 (fr) 1999-07-07
CA2151148A1 (fr) 1994-06-23
EP0673236A1 (fr) 1995-09-27

Similar Documents

Publication Publication Date Title
US5756107A (en) Formulations and methods for reducing skin irritation
US6235291B1 (en) Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
CA2208078C (fr) Formulations et procedes pour diminuer l'irritation de la peau
US5804203A (en) Topical product formulations containing strontium for reducing skin irritation
US7404967B2 (en) Topical product formulations containing strontium for reducing skin irritation
JP3112844B2 (ja) サブスタンスｐアンタゴニストとしてランタニド、マンガン、またはイットリウムを含有する組成物
US6248763B1 (en) Composition for treating skin conditions
US20040102358A1 (en) Composition for treating skin conditions
CA2212127A1 (fr) Formulations et procedes permettant de reduire l'irritation cutanee
WO1996023490A9 (fr) Formulations et procedes permettant de reduire l'irritation cutanee
NZ248069A (en) Topical liquid composition for skin application comprising retinoic acid or an ester for treating dermatological disorders, together with alpha tocopherol to reduce skin irritation
WO1996019183A9 (fr) Formulations et procedes pour diminuer l'irritation de la peau
US6267972B1 (en) Cosmetic/pharmaceutical compositions comprising β-adrenergic agonists/substance P antagonists
AU680222B2 (en) Method for stimulating production of heme oxygenase using vitamin B12
JP3054587B2 (ja) 化粧品組成物におけるエチレンジアミン誘導体の使用および刺激性副作用を有する成分を含有する化粧品組成物
US5674505A (en) Method for treating non-ocular epithelial disorders via increasing heme oxygenase levels and/or decreasing levels of arachidonic acid derivatives
RU2007101243A (ru) Композиции и способы для местного применения для состояний, связанных с эпителием
US6333042B1 (en) Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
US6110472A (en) Vitamin B12 containing scalp and skin treatment compositions
JPH10167957A (ja) 細胞間接着抑制剤
EP0955032A1 (fr) Produit de beaute
JPH03112912A (ja) 化粧料組成物
WO1983000628A1 (fr) Procede de traitement de l'acne vulgaire et composition contenant du peroxyde de carbamide
US20040204492A1 (en) Topical composition and method for treating seborrheic dermatitis
US20230293451A1 (en) Stimulation of hair growth

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA FI JP KR NO NZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2151148

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994903578

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994903578

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994903578

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载